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Background
A patient comes to you asking whether using a mat-
tress cover would help her allergic rhinitis. You know
that she is allergic to house-dust mites and you know
also that bedding covers have been widely recom-
mended for allergic rhinitis, not least by several clinical
guidelines.1,2 You have also heard however that some
doubt has been cast on the evidence supporting these
recommendations. With your interest raised, you deter-
mine to try to find out for yourself...
So what is the question?
To get the right answer one first needs the right ques-
tion. One question might be: ‘In people with allergic
rhinitis, what is the effect of impermeable bedding cov-
ers on the symptoms of allergic rhinitis?’
The type of evidence to look for, and
where to look for it
Treatments are best assessed by randomised con-
trolled trials.* If more than one trial has been per-
formed, the best evidence, if available, will usually
come from a systematic review* of the valid ran-
domised controlled trials. Next best would be the ran-
domised controlled trials themselves. If they do not
exist, one must rely on less rigorous sources of evi-
dence, and make allowance for the loss of rigour. In a
so-called ‘hierarchy of evidence’, the next-best sources
of evidence on interventions are usually, in order, non-
randomised controlled trials, case-control studies, case
reports or case series, and expert opinion. 
For an intervention, a first port of call would be the
Cochrane Library.* A next option is the ‘Clinical
Queries’ feature of Pubmed. This feature automatically
uses specially designed search strategies to filter out
the ‘hits’ most likely to answer clinical questions about
therapy, or diagnosis, or aetiology or prognosis. It is
also possible to search for systematic reviews on your
topic of interest.
What was found
A Cochrane review does exist, which found that: ‘Trials
to date have been small and of poor methodological
quality making it difficult to offer definitive recommen-
dations...’3 (unfortunately not an uncommon finding).
However, this was last updated in February 2003. 
Maybe something useful had been published
since then? A next step would be to search PubMed,
using the ‘Clinical Queries’ option you see in the
left-hand column of the PubMed webpage
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi).
Choosing the ‘Find Systematic Reviews’ box, and typ-
ing in ‘allergic rhinitis AND covers’, two reviews were
identified. One was the Cochrane review.3 The other
came from a prestigious institution and was even avail-
able on-line.4 This review however appeared not to be
systematic. The abstract said it was a ‘critical review’
rather than a systematic one, and mentioned no meth-
ods of the review (a rough rule of thumb is that true
systematic reviews have methods sections, even in
the abstract). The article also cost $30. Next port of call
was the ‘Search by Clinical Study Category’ in ‘Clinical
Queries’. Typing in the same search terms, clicking on
‘therapy’ to describe the kind of information you were
after, and choosing a ‘narrow specific search’, four
‘hits’ popped up. One from July 2003 dealt specifically
with bedding covers and allergic rhinitis.5
What the authors did
A randomised controlled trial of 279 patients (average
age 26 years) with allergic rhinitis and house-dust mite
sensitisation who received either impermeable covers
for mattress, pillows and duvet or blanket, or identical
(except non-permeable) control covers. The primary
outcome of the trial was a change in a rhinitis symptom
score (out of 100) after 12 months.
Results
Other findings
• There was a significant reduction in house-dust mite
concentrations in the mattresses of the imperme-
able-cover group, and this was not seen in the con-
trol group. 
• No subgroups of patients were identified in whom
the intervention worked differently.
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Outcome Bedding covers Control
Rhinitis-specific 
symptom score (/100)
At baseline 52.2 49.8
After 12 months 42.3 39.0
Mean improvement  9.8 (4.4 to 15.3) 10.9 (5.1 to 16.7)
(with 95%  
confidence interval)
Difference between -1.0 (-8.9 to 6.9)
improvements
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Some comments
• The bedding covers succeeded in reducing house-
dust mite concentrations but did not improve symp-
toms. Beware of research that uses intermediate or
‘surrogate’ outcomes, such as laboratory results or
mite counts, rather than clinically meaningful out-
comes such as symptoms. One has to assume that
the ‘surrogate’ outcome actually represents
improved health. This study illustrates that this is not
necessarily true.
• The point estimate (‘best guess’) from this study is
that there was a difference in symptom scores of
one point in favour of the control. However, the 95%
confidence interval indicates that that the true size of
the difference (which is never exactly known) has a
95% chance of falling somewhere between a score
of 8.9 points less to 6.9 points more for the bedding
group. Thus, if an improvement of less than seven
points could still be a meaningful improvement, then
this study does not exclude a meaningful effect.
Neither does it exclude meaningful harm.
Remember that lack of evidence of an effect is not
the same as evidence of no effect. 
• The symptom score actually improved by 9.8 points
during the trial, which was statistically highly signifi-
cant* (p<0.001). However, the control group
improved even more, by 10.9 points. Something else
was happening during the course of the trial that
resulted in improvement and had nothing to do with
bedding covers (probably a phenomenon called
regression to the mean, but you won’t want to know
about that). The point is that, if a control group had
not been used to see what happened without the
intervention, it would probably have been falsely
concluded that bedding covers are effective. Beware
of uncontrolled ‘before-after’ studies.
• When the Cochrane systematic review is next
updated, it will most likely include the trial featured
here, and any other valid new trials that we might
have missed in our quick search.
References
1. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus
statement on the treatment of allergic rhinitis. European Academy
of Allergology and Clinical Immunology. Allergy 2000; 55: 116-134.
2. International Consensus Report on the diagnosis and management
of rhinitis. International Rhinitis Management Working Group.
Allergy 1994; 49 (19 Suppl): 1-34.
3. Sheikh A, Hurwitz B. House dust mite avoidance measures for
perennial allergic rhinitis. The Cochrane Database of Systematic
Reviews 2001, Issue 4. Art. No.: CD001563. DOI:
10.1002/14651858.CD001563
4. Sanico AM. Latest developments in the management of allergic
rhinitis. Clin Rev Allergy Immunol 2004; 27: 181-189.
5. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable
covers for bedding in patients with allergic rhinitis. N Engl J Med
2003; 349: 237-246.
*Some terms explained 
Cochrane Library. An electronic collection of over
2 000 high-quality systematic reviews, it is a good first
port of call when looking for evidence on interven-
tions. In South Africa the Cochrane Library is accessi-
ble (after registering) free of charge at
http://www.sahealthinfo.org/evidence/databases.htm
Randomised controlled trial. In a controlled trial
patients are actively allocated to either receive
treatment or be in a control group. The control
group allows comparison of the outcome with
treatment and the outcome without treatment.
However the two groups need to be as similar as
possible before the trial starts, so that any differ-
ences at the end can be attributed to the treat-
ment. Randomly allocating participants to
treatment or control is the best way we know of
obtaining groups that are comparable.
Statistical significance, p values. The p value is
the probability that the observed or greater differ-
ence between groups has occurred by chance, if
there were in fact no real difference. If this proba-
bility is less than 1/20 (a p value of less than 0.05),
we would conventionally accept that the finding is
not due to chance, i.e. ‘statistically significant’.
This cut-off of 0.05 is entirely arbitrary. Because
chance variation has a greater influence on the
findings of smaller studies, the p value is affected
by the sample size. In this study the symptom
score in the impermeable cover group actually
improved by 9.8 points during the trial, which was
statistically highly significant (p<0.001), i.e. less
than one chance in 1 000 that the finding was due
to chance. The difference is highly unlikely to be
due to chance, but it is not necessarily due to the
covers, as is seen in this trial (an even greater
improvement occurred in the control group).
Systematic review. This is a literature review
conducted itself like a research study, in order to
minimise the many unintended (and sometimes
subtle) biases that can creep into traditional litera-
ture reviews. It uses specified systematic meth-
ods to identify, appraise and summarise studies
aimed at answering a defined question. A
Cochrane review is a systematic review per-
formed under the auspices of an international col-
laboration called the Cochrane Collaboration.
There are however many systematic reviews per-
formed outside of the Cochrane Collaboration.
           
